⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902017 | 0.96 | — | — | |
| SCHEMBL13858763 | 0.67 | — | — | |
| SCHEMBL27468149 | 0.61 | — | — | |
| SCHEMBL21331736 | 0.61 | — | — | |
| SCHEMBL8738119 | 0.58 | — | — | |
| SCHEMBL5707703 | 0.55 | — | — | |
| SCHEMBL669547 | 0.51 | — | — | |
| SCHEMBL17145158 | 0.48 | — | — | |
| SCHEMBL11631530 | 0.48 | — | — | |
| Hno SCHEMBL1232498 | 0.43 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661560-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | claimed |
| WO-2019025440-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | claimed |
| WO-2018153969-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH RADIUM-223 SALT | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | claimed |
| EP-3177619-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-14 | — | — | EP | claimed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | claimed |
| WO-2023151662-A1 | ANDROGEN RECEPTOR ACTIVITY REGULATOR AND USE THEREOF | 上海奕拓医药科技有限责任公司 | 2023-08-17 | — | — | WO | disclosed |
| EP-4013508-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | disclosed |
| CN-114466850-A | [1,2,4] triazolo [1,5-C ] quinazolin-5-amines | 拜耳股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-110204544-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110256427-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-108699057-B | 5-substituted 2- (morpholin-4-yl) -1, 7-naphthyridines | 拜耳医药股份公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2018153973-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| CN-101648906-B | Insecticidal N-substituted sulfoximines | DOW AGROSCIENCES LLC | 2012-07-11 | — | — | CN | disclosed |
| CN-101648906-A | Insecticidal N-substituted sulfoximines | DOW AGROSCIENCES LLC US | 2010-02-17 | — | — | CN | disclosed |
| EP-1863785-B1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-02 | — | — | EP | disclosed |
| EP-1863785-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING CMPLEMENT-MEDIATED DESEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| CN-1942442-A | Insecticidal N-substituted sulfenimides | DOW AGROSCIENCES LLC (US) | 2007-04-04 | — | — | CN | disclosed |
| EP-1732895-A2 | INSECTICIDAL N-SUBSTITUTED SULFOXIMINES | Dow Agrosciences LLC (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006101860-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006060029-A2 | INSECTICIDAL N-SUBSTITUTED SULFOXIMINES | DOW AGROSCIENCES LLC (US) | 2006-06-08 | — | — | WO | disclosed |